Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Shares Issued (2022 - 2025)

Historic Shares Issued for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to $122000.0.

  • Taysha Gene Therapies' Shares Issued rose 9365.08% to $122000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $197000.0, marking a year-over-year decrease of 6345.08%. This contributed to the annual value of $89000.0 for FY2024, which is 8220.0% down from last year.
  • Per Taysha Gene Therapies' latest filing, its Shares Issued stood at $122000.0 for Q3 2025, which was up 9365.08% from $75000.0 recorded in Q1 2025.
  • Taysha Gene Therapies' Shares Issued's 5-year high stood at $450000.0 during Q3 2023, with a 5-year trough of -$11.4 million in Q4 2022.
  • Its 4-year average for Shares Issued is -$1.1 million, with a median of $63000.0 in 2024.
  • Its Shares Issued has fluctuated over the past 5 years, first plummeted by 8600.0% in 2024, then skyrocketed by 18846.15% in 2025.
  • Over the past 4 years, Taysha Gene Therapies' Shares Issued (Quarter) stood at -$11.4 million in 2022, then soared by 103.95% to $450000.0 in 2023, then plummeted by 86.0% to $63000.0 in 2024, then surged by 93.65% to $122000.0 in 2025.
  • Its Shares Issued stands at $122000.0 for Q3 2025, versus $75000.0 for Q1 2025 and $63000.0 for Q3 2024.